257 related articles for article (PubMed ID: 30464698)
1. Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia.
Owen C; Gerrie AS; Banerji V; Assouline S; Chen C; Robinson KS; Lye E; Fraser G
Curr Oncol; 2018 Oct; 25(5):e461-e474. PubMed ID: 30464698
[TBL] [Abstract][Full Text] [Related]
2. Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update.
Owen C; Banerji V; Johnson N; Gerrie A; Aw A; Chen C; Robinson S
Leuk Res; 2023 Feb; 125():107016. PubMed ID: 36634577
[TBL] [Abstract][Full Text] [Related]
3. A Canadian evidence-based guideline for the first-line treatment of follicular lymphoma: joint consensus of the Lymphoma Canada Scientific Advisory Board.
Kuruvilla J; Assouline S; Hodgson D; MacDonald D; Stewart D; Christofides A; Komolova M; Connors J
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):59-74. PubMed ID: 25195028
[TBL] [Abstract][Full Text] [Related]
4. Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia.
Owen C; Eisinga S; Banerji V; Johnson N; Gerrie AS; Aw A; Chen C; Robinson S
Leuk Res; 2023 Oct; 133():107372. PubMed ID: 37633157
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.
Raa DGT; van der Straten L; van Gelder M; Kersting S; Levin MD; Mous R; van der Straaten HM; Nijziel MR; van der Spek E; Posthuma EFM; Visser HPJ; van der Klift M; de Heer K; Bellido M; Doorduijn JK; Bruns AHW; Raijmakers RAP; Kater AP;
Leuk Lymphoma; 2022 Oct; 63(10):2276-2289. PubMed ID: 35737364
[TBL] [Abstract][Full Text] [Related]
6. A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
Owen C; Bence-Bruckler I; Chamakhi I; Toze C; Assaily W; Christofides A; Robinson S
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):303-13. PubMed ID: 25937158
[TBL] [Abstract][Full Text] [Related]
7. What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?
Voorhies BN; Stephens DM
Curr Treat Options Oncol; 2017 Feb; 18(2):12. PubMed ID: 28243993
[TBL] [Abstract][Full Text] [Related]
8. Evidence-Based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region.
Alshemmari SH; Siddiqui MA; Pandita R; Osman HY; Cherif H; O'Brien S; Marashi M; Al Farsi K
Acta Haematol; 2024; 147(3):260-279. PubMed ID: 37751733
[TBL] [Abstract][Full Text] [Related]
9. Chronic lymphocytic leukemia: a clinical review.
Nabhan C; Rosen ST
JAMA; 2014 Dec; 312(21):2265-76. PubMed ID: 25461996
[TBL] [Abstract][Full Text] [Related]
10. Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.
García-Marco JA; Delgado J; Hernández-Rivas JA; Ramírez Payer Á; Loscertales Pueyo J; Jarque I; Abrisqueta P; Giraldo P; Martínez R; Yáñez L; Terol MJ; González M; Bosch F;
Med Clin (Barc); 2017 Apr; 148(8):381.e1-381.e9. PubMed ID: 28236475
[TBL] [Abstract][Full Text] [Related]
11. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
12. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.
Owen C; Assouline S; Kuruvilla J; Uchida C; Bellingham C; Sehn L
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):627-634.e5. PubMed ID: 26416145
[TBL] [Abstract][Full Text] [Related]
13. Frontline Treatment of the Young, Fit Patient with CLL: A Canadian Perspective.
Costello J; Kang M; Banerji V
Curr Oncol; 2021 Sep; 28(5):3825-3835. PubMed ID: 34677244
[TBL] [Abstract][Full Text] [Related]
14. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group.
Cheson BD; Bennett JM; Rai KR; Grever MR; Kay NE; Schiffer CA; Oken MM; Keating MJ; Boldt DH; Kempin SJ
Am J Hematol; 1988 Nov; 29(3):152-63. PubMed ID: 3189311
[TBL] [Abstract][Full Text] [Related]
15. Chronic Lymphocytic Leukemia: A Review of Front-line Treatment Options, With a Focus on Elderly CLL Patients.
O'Reilly A; Murphy J; Rawe S; Garvey M
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):249-256. PubMed ID: 29477297
[TBL] [Abstract][Full Text] [Related]
16. Chronic Lymphocytic Leukemia: Current Concepts.
Yu EM; Kittai A; Tabbara IA
Anticancer Res; 2015 Oct; 35(10):5149-65. PubMed ID: 26408673
[TBL] [Abstract][Full Text] [Related]
17. On the front line: first choice pharmacotherapeutics for chronic lymphocytic leukemia.
Samples LS; Graf SA
Expert Opin Pharmacother; 2018 Oct; 19(15):1675-1684. PubMed ID: 30222470
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia.
Harkins RA; Patel SP; Flowers CR
Cancer J; 2019; 25(6):418-427. PubMed ID: 31764123
[TBL] [Abstract][Full Text] [Related]
19. Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada.
Lee LJ; Toze CL; Huang SJT; Gillan TL; Connors JM; Sehn LH; Bruyere H; Leitch H; Ramadan KM; Gerrie AS
Leuk Lymphoma; 2018 Jun; 59(6):1356-1363. PubMed ID: 29032719
[TBL] [Abstract][Full Text] [Related]
20. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
